Sign In
Buy PCRX
$26.41
-0.560 (-2.08%)
At Close: Jul 31, 2026
The Daily Biotech Pulse: FDA Nod For Osmotica, OptiNose Strikes Co-promotion Deal, Orphan Drug Designation For AnaptysBio
12:00am, Thursday, 09'th Jul 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 8)
Akero Therapeutics Inc (...
The Daily Biotech Pulse: Intersect ENT Jumps On M&A Speculation, VIVUS Files For Bankruptcy
12:00am, Wednesday, 08'th Jul 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 7)
AbbVie Inc (NYSE: ABBV)...
Pacira BioSciences, Inc. Announces Pricing of $350.0 Million Aggregate Principal Amount of 0.750% Convertible Senior Notes due 2025
11:51pm, Tuesday, 07'th Jul 2020
Pacira BioSciences, Inc. (PCRX) today announced the pricing of $350.0 million aggregate principal amount of convertible senior notes due 2025 (the “notes”) in a private placement to qualified inst
Pacira BioSciences, Inc. Announces Proposed Offering of $300.0 Million Aggregate Principal Amount of Convertible Senior Notes
08:02pm, Monday, 06'th Jul 2020
Pacira BioSciences, Inc. (PCRX) today announced that it intends to offer, subject to market and other conditions, $300.0 million aggregate principal amount of convertible senior notes due 2025 (the �
Pacira BioSciences Reports Preliminary Total Revenue of $75.5 Million for Second Quarter of 2020
08:01pm, Monday, 06'th Jul 2020
Pacira BioSciences, Inc. (PCRX), a leading provider of innovative non-opioid pain management options, today reported preliminary unaudited net revenue of $75.5 million for the second quarter of 2020,
Pacira Biosciences (NASDAQ:PCRX) Given New $64.00 Price Target at Needham & Company LLC
07:44am, Monday, 06'th Jul 2020
Pacira Biosciences (NASDAQ:PCRX) had its price objective boosted by analysts at Needham & Company LLC from $52.00 to $64.00 in a research report issued on Monday, Briefing.com Automated Import reports
Pacira Biosciences (NASDAQ:PCRX) Earns Overweight Rating from Piper Sandler
07:44am, Monday, 06'th Jul 2020
Pacira Biosciences (NASDAQ:PCRX)‘s stock had its “overweight” rating reiterated by equities research analysts at Piper Sandler in a research report issued to clients and investors on Monday, The
So far Sunday, July 5, NASDAQ is down -2.97% and the S&P is down -2.01%. Here are this morning’s most
So far Saturday, July 4, NASDAQ is down -2.97% and the S&P is down -2.01%. Here are this morning’s most
Northland Securities Raises Pacira Biosciences (NASDAQ:PCRX) Price Target to $54.00
08:20am, Saturday, 04'th Jul 2020
Pacira Biosciences (NASDAQ:PCRX) had its target price hoisted by Northland Securities from $50.00 to $54.00 in a report released on Tuesday, The Fly reports. The firm currently has a market perform ra
Intravenous Stopcock Market to Surpass US$ 570.4 Million globally by end of 2027, Says CMI
12:00am, Friday, 03'rd Jul 2020
North America region is projected to be the most lucrative region in intravenous stopcock market, owing to the rising prevalence of chronic diseases.
Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX) and Pfizer (NYSE: PFE) - Markets
03:52pm, Thursday, 02'nd Jul 2020
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Neurocrine (NBIX
Pacira BioSciences Announces Conclusion of EXPAREL Agreement with DePuy Synthes
11:30am, Thursday, 02'nd Jul 2020
Pacira BioSciences, Inc. (PCRX), a leading provider of innovative non-opioid pain management options, today announced that the company has notified DePuy Synthes Sales Inc. that the agreement between
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 1)
AbbVie Inc (NYSE: ABBV)
ADC...
The Daily Biotech Pulse: T2 Biosystems Launches COVID-19 Test, Akero Aces Midstage NASH Study, Aravive Added to Russell Indexes
12:00am, Wednesday, 01'st Jul 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 30)
ADC Therapeutics SA (NYSE:...
